APU
WINT

Alpine Partners USVI’s Windtree Therapeutics Inc WINT Stock Holding History

Alpine Partners USVI’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-727
Closed -$15K – 167
2013
Q2 		$15K Buy
+727
New +$17.9K ﹤0.01% 185

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alpine Partners USVI's WINT Position: Q3 2013 in Review

Alpine Partners USVI sold out of Windtree Therapeutics Inc (WINT) in Q3 2013, closing a stake of 727 shares — an estimated $15K sold.

Alpine Partners USVI first reported a position in WINT in Q2 2013 and held it in 1 quarter. The position peaked at $15K in Q2 2013. 50 funds tracked by Wall St. Rank hold WINT as of Q3 2013.

  • Alpine Partners USVI reported no remaining Windtree Therapeutics Inc position as of Q3 2013 after selling out during the quarter.
  • Alpine Partners USVI sold 727 Windtree Therapeutics Inc shares in Q3 2013, an estimated $15K.
  • Alpine Partners USVI first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 1 quarter.
  • Alpine Partners USVI's Windtree Therapeutics Inc position peaked at $15K in Q2 2013.
  • 50 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q3 2013.

Based on Alpine Partners USVI's 13F filing for Q3 2013, filed 14 Nov 2013.